Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia.

Current opinion in hematology - 1 Jan 2005

Levis Mark

Abstract excerpt

PURPOSE OF REVIEW: This review outlines recent advances in the development of small-molecule inhibitors of molecular signaling pathways for the treatment of acute myeloid leukemia (AML). These compounds are typically targeted against components of the tyrosine kinase-Ras-Map kinase pathway that have been activated by mutation. RECENT FINDINGS: Several agents have been tested in phase 2 trials, with only modest...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Design
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mitogen-Activated Protein Kinases

Share to Models, Biological

Share to Protein-Tyrosine Kinases

Share to ras Proteins

Source

Identifiers

PMID: 15604892
DOI: 10.1097/01.moh.0000148761.23036.e6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia.PMID 15604892Read ↗

Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia.Semantic proximity Read ↗

Mechanisms of Resistance to Small Molecules in Acute Myeloid LeukemiaSemantic proximity Read ↗

Emerging small molecular inhibitors as targeted therapies for high-risk acute myeloid leukemias.Semantic proximity Read ↗

Role of farnesyltransferase inhibitors in hematologic malignancies.Semantic proximity Read ↗

Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia.Semantic proximity Read ↗

Molecular targeting in acute myeloid leukemiaSemantic proximity Read ↗

Molecular targets in acute myelogenous leukemia.Semantic proximity Read ↗

Second line small molecule therapy options for treating chronic myeloid leukemia.Semantic proximity Read ↗

Small molecule inhibitors of RAS proteins with oncogenic mutations.Semantic proximity Read ↗

Identification of small molecules that support human leukemia stem cell activity ex vivoSemantic proximity Read ↗

Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?Semantic proximity Read ↗

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.